Humana (HUM) Deepens MA Neuromodulation Coverage: A Clue to Its Margin Recovery Strategy?

In early October 2026, BlueWind Medical announced that Humana began covering implantable tibial neuromodulation therapy for urgency urinary incontinence, including BlueWind’s Revi System, across its Medicare Advantage membership of about 11 million enrollees. This coverage decision, backed by multi‑year OASIS clinical data and a new AMA Category I CPT code for subfascial tibial neuromodulation, highlights how Humana may be broadening access to advanced, home‑managed therapies for seniors...